BC Innovations | Dec 19, 2019
Distillery Therapeutics

Depleting platelets of inhibiting SOCS3 for atherosclerosis

DISEASE CATEGORY: Cardiovascular INDICATION: Atherosclerosis Platelet depletion or inhibition of SOCS3, a platelet-induced regulator of macrophage polarization, could treat atherosclerosis. Blood levels of SOCS3 RNA were higher in 61 women presenting with myocardial infarction (MI)...
BC Innovations | Aug 22, 2017
Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Nanoparticles that promote tumor platelet phagocytosis could be used to delivery cancer therapies. The nanoparticles consist of a polyethylenimine (PEI)-poly(glycolic acid) core that contains drug cargo and a mAb targeting glycoprotein Ib (platelet)...
BC Innovations | Jun 7, 2017
Distillery Therapeutics

Cardiovascular

INDICATION: Thrombosis Mouse studies suggest inhibiting the MAC-1 - GP1BA interaction could help treat thrombosis. In a mouse model of microvascular thrombosis, knockout of MAC-1 decreased platelet accumulation in arterioles compared with normal MAC-1 expression. In...
BC Innovations | Feb 25, 2010
Targets & Mechanisms

Targeting platelets in RA

Harvard Medical School researchers have shown that platelets can contribute to inflammatory arthritis and have identified a collagen receptor on these cells that could be a target for treating RA. 1 But inhibiting the collagen...
BC Innovations | Feb 12, 2009
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Ischemia; reperfusion injury von Willebrand factor (vWF); glycoprotein Ib a-polypeptide (GP1BA; GP1Ba) Studies in mice suggest that inhibiting the GPB1a-vWF...
Items per page:
1 - 5 of 5